Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 4
Submit an article Journal homepage
30
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Efficacy of orlistat in obese patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

Abdelrahman Mahmouda Faculty of Medicine, Minia University, Minia, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7514-1623
, MBBChORCID Icon,
Islam Mohamedb Department of Internal Medicine, University of Missouri, Kansas City, Missouri, USA
, MD,
Mohamed Abuelazmc Faculty of Medicine, Tanta University, Tanta, Egypt
, MBBCh,
Ali Ashraf Salah Ahmeda Faculty of Medicine, Minia University, Minia, Egypt
, MBBCh,
Abdallah Saeedc Faculty of Medicine, Tanta University, Tanta, Egypt
, MBBCh,
Mahmoud Elshinawya Faculty of Medicine, Minia University, Minia, Egypt
, MBBCh,
Omar Almaadawyd Department of Internal Medicine, MedStar Health, Baltimore, Maryland, USA
, MD &
Basel Abdelazeeme Cardiology Department, West Virginia University, Morgantown, West Virginia, USA
, MD show all
Pages 603-612 | Received 09 Nov 2023, Accepted 18 Mar 2024, Published online: 09 Apr 2024

  • Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64. doi:10.1016/j.jhep.2014.12.012.
  • Arshad T, Golabi P, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease in North America. Curr Pharm Des. 2020;26(10):993–997. doi:10.2174/1381612826666200303114934.
  • Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20(18):5320–5330. doi:10.3748/wjg.v20.i18.5320.
  • Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi:10.1016/s0140-6736(20)32511-3.
  • Yang JD, Kim B, Sanderson SO, et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976–2008. Mayo Clin Proc. 2012;87(1):9–16. doi:10.1016/j.mayocp.2011.07.001.
  • Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2018;9(1):90–96. doi:10.3892/br.2018.1100.
  • AASLD. https://www.aasld.org/new-masld-nomenclature.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
  • Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142. doi:10.1002/14651858.Ed000142.
  • Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
  • Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–998. doi:10.1136/bmj.39490.551019.BE.
  • Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD.
  • RevMan. Cochrane Training [Internet]. https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman. Accessed August 3, 2021.
  • Higgins JPT, Thomas J, Chandler J, et al (eds.). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane, 2022.
  • Esmail VAW, Mohammed MO, Al-Nimer MSM. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab J Gastroenterol. 2021;22(1):1–5. doi:10.1016/j.ajg.2020.12.005.
  • Feng X, Lin Y, Zhuo S, et al. Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: a randomized controlled trial. Am J Clin Nutr. 2023;117(4):691–700. doi:10.1016/j.ajcnut.2023.02.008.
  • Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49(1):80–86. doi:10.1002/hep.22575.
  • Ye J, Wu Y, Li F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol. 2019;12:1756284819879047. doi:10.1177/1756284819879047.
  • Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31(1):53–65. doi:10.2165/00002018-200831010-00005.
  • Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S12–S23.
  • McClendon KS, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf. 2009;8(6):727–744. doi:10.1517/14740330903321485.
  • Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123–1128. doi:10.2337/diacare.25.7.1123.
  • Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288–1294. doi:10.2337/diacare.21.8.1288.
  • Kelley DE, Jneidi M. Orlistat in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2002;3(5):599–605. doi:10.1517/14656566.3.5.599.
  • Shi YF, Pan CY, Hill J, Gao Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabet Med. 2005;22(12):1737–1743. doi:10.1111/j.1464-5491.2005.01723.x.
  • Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160(9):1321–1326. doi:10.1001/archinte.160.9.1321.
  • Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther. 2012;37(2):187–195. doi:10.1111/j.1365-2710.2011.01280.x.
  • Zhao P, Saltiel AR. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases. J Biol Chem. 2020;295(34):12279–12289. doi:10.1074/jbc.REV120.011356.
  • Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021;18(10):5227. doi:10.3390/ijerph18105227.
  • Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022;163(3):764–774.e1. doi:10.1053/j.gastro.2022.06.023.
  • Koutoukidis DA, Astbury NM, Tudor KE, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(9):1262–1271. doi:10.1001/jamainternmed.2019.2248.
  • Properzi C, O’Sullivan TA, Sherriff JL, et al. Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial. Hepatology. 2018;68(5):1741–1754. doi:10.1002/hep.30076.
  • Kouvari M, Boutari C, Chrysohoou C, et al. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. Clin Nutr. 2021;40(5):3314–3324. doi:10.1016/j.clnu.2020.10.058.
  • Abuelazm MT, Mohamed I, Naeem A, et al. Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2024;36(4):371–381. doi:10.1097/meg.0000000000002715.
  • Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol. 2016;65(4):791–797. doi:10.1016/j.jhep.2016.05.026.
  • St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009;50(1):68–76. doi:10.1002/hep.22940.
  • Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106(3):460–468; quiz 469. doi:10.1038/ajg.2010.488.
  • Ong Lopez AMC, Pajimna JAT. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. doi:10.1038/s41598-024-52603-5.
  • Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73. doi:10.3390/metabo11020073.
  • Ali Khan R, Kapur P, Jain A, Farah F, Bhandari U. Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. Ther Clin Risk Manag. 2017;13:139–149. doi:10.2147/tcrm.S124621.
  • Kujawska-Łuczak M, Musialik K, Szulińska M, et al. The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study. Arch Med Sci. 2017;13(4):725–731. doi:10.5114/aoms.2016.62014.
  • Keller KB, Lemberg L. Obesity and the metabolic syndrome. Am J Crit Care. 2003;12(2):167–170.
  • Izzo JL Jr. Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment. J Clin Hypertens. 2003;5(6 Suppl 4):3–10. doi:10.1111/j.1524-6175.2003.02670.x.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.